Rimonabant for the treatment of obesity

Ashish Samat, Brian Tomlinson, Shahrad Taheri, G. Neil Thomas

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocannabinoid system (ECS) was discovered in the early 1990s in relation to work on the action of components of marijuana. Central activation of the ECS promotes food ingestion. The endogenous cannabinoids exert their pharmacologic action through interaction with the specific receptors, CB1 and CB2. CB1 receptors are located predominantly in the brain and peripherally in adipose tissue, liver, skeletal muscle and the gastrointestinal tract. In July 2006, European regulatory authorities approved the use of rimonabant, SR141716, a selective CB1 receptor antagonist, in obese patients (BMI ≥30kg/m2, or >27kg/m2 with complications). However, in June 2007, despite extensive clinical trial data, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that the safety of rimonabant had not been adequately demonstrated by the manufacturer Sanofi-Aventis; the full application was subsequently withdrawn. This review article provides evidence and outlines some patents for the use of rimonabant and potential safety concerns which still prevent its use in the single largest market for drugs of its kind.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalRecent Patents on Cardiovascular Drug Discovery
Volume3
Issue number3
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

rimonabant
Cannabinoid Receptor CB1
Obesity
Endocannabinoids
Cannabinoids
Pharmacy and Therapeutics Committee
Cannabinoid Receptor CB2
Pharmacologic Actions
Safety
Patents
Advisory Committees
Therapeutics
Cannabis
Gastrointestinal Tract
Adipose Tissue
Skeletal Muscle
Public Health
Eating
Clinical Trials
Food

Keywords

  • ARPEGGIO
  • AUDITOR
  • CRESCENDO
  • Endocannabinoid system
  • Obesity
  • RAPSODI
  • Rimonabant
  • RIO ADAGIO-Lipids
  • SERENADE
  • STRADIVARIUS
  • Vascular disease risk factors
  • VICTORIA
  • Visceral fat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Rimonabant for the treatment of obesity. / Samat, Ashish; Tomlinson, Brian; Taheri, Shahrad; Thomas, G. Neil.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 3, No. 3, 2008, p. 187-193.

Research output: Contribution to journalReview article

Samat, Ashish ; Tomlinson, Brian ; Taheri, Shahrad ; Thomas, G. Neil. / Rimonabant for the treatment of obesity. In: Recent Patents on Cardiovascular Drug Discovery. 2008 ; Vol. 3, No. 3. pp. 187-193.
@article{e79f551bcef64993a5bd99481659e9fa,
title = "Rimonabant for the treatment of obesity",
abstract = "Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocannabinoid system (ECS) was discovered in the early 1990s in relation to work on the action of components of marijuana. Central activation of the ECS promotes food ingestion. The endogenous cannabinoids exert their pharmacologic action through interaction with the specific receptors, CB1 and CB2. CB1 receptors are located predominantly in the brain and peripherally in adipose tissue, liver, skeletal muscle and the gastrointestinal tract. In July 2006, European regulatory authorities approved the use of rimonabant, SR141716, a selective CB1 receptor antagonist, in obese patients (BMI ≥30kg/m2, or >27kg/m2 with complications). However, in June 2007, despite extensive clinical trial data, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that the safety of rimonabant had not been adequately demonstrated by the manufacturer Sanofi-Aventis; the full application was subsequently withdrawn. This review article provides evidence and outlines some patents for the use of rimonabant and potential safety concerns which still prevent its use in the single largest market for drugs of its kind.",
keywords = "ARPEGGIO, AUDITOR, CRESCENDO, Endocannabinoid system, Obesity, RAPSODI, Rimonabant, RIO ADAGIO-Lipids, SERENADE, STRADIVARIUS, Vascular disease risk factors, VICTORIA, Visceral fat",
author = "Ashish Samat and Brian Tomlinson and Shahrad Taheri and Thomas, {G. Neil}",
year = "2008",
doi = "10.2174/157489008786264014",
language = "English",
volume = "3",
pages = "187--193",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Rimonabant for the treatment of obesity

AU - Samat, Ashish

AU - Tomlinson, Brian

AU - Taheri, Shahrad

AU - Thomas, G. Neil

PY - 2008

Y1 - 2008

N2 - Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocannabinoid system (ECS) was discovered in the early 1990s in relation to work on the action of components of marijuana. Central activation of the ECS promotes food ingestion. The endogenous cannabinoids exert their pharmacologic action through interaction with the specific receptors, CB1 and CB2. CB1 receptors are located predominantly in the brain and peripherally in adipose tissue, liver, skeletal muscle and the gastrointestinal tract. In July 2006, European regulatory authorities approved the use of rimonabant, SR141716, a selective CB1 receptor antagonist, in obese patients (BMI ≥30kg/m2, or >27kg/m2 with complications). However, in June 2007, despite extensive clinical trial data, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that the safety of rimonabant had not been adequately demonstrated by the manufacturer Sanofi-Aventis; the full application was subsequently withdrawn. This review article provides evidence and outlines some patents for the use of rimonabant and potential safety concerns which still prevent its use in the single largest market for drugs of its kind.

AB - Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocannabinoid system (ECS) was discovered in the early 1990s in relation to work on the action of components of marijuana. Central activation of the ECS promotes food ingestion. The endogenous cannabinoids exert their pharmacologic action through interaction with the specific receptors, CB1 and CB2. CB1 receptors are located predominantly in the brain and peripherally in adipose tissue, liver, skeletal muscle and the gastrointestinal tract. In July 2006, European regulatory authorities approved the use of rimonabant, SR141716, a selective CB1 receptor antagonist, in obese patients (BMI ≥30kg/m2, or >27kg/m2 with complications). However, in June 2007, despite extensive clinical trial data, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that the safety of rimonabant had not been adequately demonstrated by the manufacturer Sanofi-Aventis; the full application was subsequently withdrawn. This review article provides evidence and outlines some patents for the use of rimonabant and potential safety concerns which still prevent its use in the single largest market for drugs of its kind.

KW - ARPEGGIO

KW - AUDITOR

KW - CRESCENDO

KW - Endocannabinoid system

KW - Obesity

KW - RAPSODI

KW - Rimonabant

KW - RIO ADAGIO-Lipids

KW - SERENADE

KW - STRADIVARIUS

KW - Vascular disease risk factors

KW - VICTORIA

KW - Visceral fat

UR - http://www.scopus.com/inward/record.url?scp=58149190820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149190820&partnerID=8YFLogxK

U2 - 10.2174/157489008786264014

DO - 10.2174/157489008786264014

M3 - Review article

C2 - 18991793

AN - SCOPUS:58149190820

VL - 3

SP - 187

EP - 193

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 3

ER -